Alnylam’s commitment to patients and their families is not only to develop therapies with the potential for a positive impact on patient health but also to serve the patient communities through education, empathy, and awareness. Over the course of the year, there are a number of initiatives, which are supported by patient advocacy organizations to raise disease awareness. These initiatives encourage and inspire us to connect with the larger community to raise awareness amongst the general public and decision-makers in an effort to gain insights into unmet needs and identify ways to improve the lives of those who are affected by these diseases.
World Hepatitis Day
July 28th is World Hepatitis Day—a day, since 2010, the World Health Organization (WHO) has set as one of only four official disease-specific world health days. World Hepatitis Day is celebrated each year with the goal to bring awareness about viral hepatitis, to call for patient access to the best treatments, better prevention programs and government action to eradicate this disease as a public health threat by 2030.
Along with the World Hepatitis Alliance (WHA)—a group of 230 patient-led and patient-driven organizations—World Hepatitis Day is led by global leaders who strive to improve the lives of over 400 million people affected by chronic viral hepatitis through better awareness, prevention, care, support, and access to treatment.
Alnylam is also doing its part to eliminate viral hepatitis, not only through its development of our Hepatic Infectious Disease pipeline, but also by partnering with WHO and WHA in the “NOhep” campaign for World Hepatitis Day. Alnylam employees across the globe wore the message of “NoHep” throughout the day and participated in other awareness activities including an educational seminar—which focused on Alnylam’s own robust HBV program and commitment to serve those who are affected every day by viral hepatitis.